Pharmaceuticals

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Two specialist investors are merging to create the world's largest dedicated healthcare fund, aiming to reshape global health innovation from West to East.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.

A new partnership aims to solve one of biotech's biggest challenges, expanding powerful gene therapies beyond the liver to treat a wider range of diseases.

Ozari Health launches a nationwide service for affordable compounded semaglutide, navigating a complex and increasingly regulated market for GLP-1 drugs.

New projects leverage AI, gene therapy advances, and diverse workforce initiatives to bolster America's manufacturing and secure its talent pipeline.

Health AI firm Vi secures unicorn status with a $145M deal while launching new AI agents. But can its vision of 'health abundance' overcome ethical hurdles?

Amid global tensions, a Hong Kong summit showcases China's vision for a new world order and the city's bid to remain a vital international hub.

The equipment giant's top honor from VETS Indexes is more than a recognition; it's a blueprint for building a stronger, more resilient workforce.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

New research on the gut-brain axis and smarter antibiotic use is transforming veterinary medicine, moving from theory to practice for healthier pets.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Rancho BioSciences' new OmicsHQ platform offers analysis-ready datasets, aiming to eliminate data cleanup and accelerate AI-driven drug discovery.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

With backing from Bain Capital and Armistice, the life sciences firm's latest offering aims to fund its push to automate pharmaceutical quality control.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

Quince Therapeutics' drug LAM-001 posts strong Phase 2a data, showing meaningful functional gains for patients with severe pulmonary hypertension.